Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.
- Exclusive worldwide license to CAR technology from Mayo Clinic
- CAR-engineered MSCs to improve targeting and immunomodulation
- Immediate applications in ulcerative colitis, Crohn's disease, and lupus nephritis
- Acquisition completed via ASX share issuance with Mayo Clinic support
- Builds on Mesoblast's FDA-approved MSC product Ryoncil
Strategic Acquisition of CAR Platform Enhances MSC Therapy Potential
Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has taken a decisive step to sharpen the precision of its cell therapies by acquiring an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. Developed by Mayo Clinic researchers and published in Nature Biomedical Engineering, this platform is engineered to augment the targeting capabilities of mesenchymal stromal cells (MSCs), the backbone of Mesoblast’s inflammatory disease treatments.
The CAR technology is designed to genetically engineer MSCs to home more effectively to inflamed tissues, thereby boosting their immunomodulatory and regenerative properties. Mesoblast’s existing MSC therapies already benefit from inherent homing abilities, but this innovation promises a substantial leap in potency and specificity, potentially transforming treatment outcomes in complex inflammatory and autoimmune conditions.
Targeting Difficult-to-Treat Inflammatory Diseases
Immediate clinical opportunities include enhanced therapies for ulcerative colitis and Crohn’s disease, where inflamed bowel tissue can be targeted with CAR-engineered MSCs. Additionally, Mesoblast plans to develop CAR-MSCs expressing CD19 to tackle lupus nephritis and other B cell-mediated autoimmune diseases, conditions that demand durable and safe immunomodulation.
The exclusive license was secured through the acquisition of a Mayo Clinic spinout, with Mayo Clinic continuing to provide in-kind support including GMP manufacturing assistance. The deal was structured via the issuance of ASX ordinary shares, underscoring Mesoblast’s commitment to advancing its pipeline through strategic partnerships and intellectual property expansion.
Building on FDA-Approved Foundations and Commercial Momentum
Mesoblast’s FDA-approved MSC therapy, Ryoncil (remestemcel-L-rknd), currently indicated for steroid-refractory acute graft-versus-host disease in paediatric patients, sets a strong regulatory and commercial foundation. The company is actively developing Ryoncil for additional inflammatory indications, including biologic-resistant inflammatory bowel disease.
This acquisition complements Mesoblast’s ongoing clinical progress, which includes the recent FDA clearance to launch a registrational trial of Ryoncil in Duchenne Muscular Dystrophy, a move that highlights the company’s expanding therapeutic ambitions beyond its current markets. The CAR platform could further diversify and strengthen Mesoblast’s product portfolio, enhancing its competitive positioning in the cell therapy sector.
Mesoblast’s robust intellectual property portfolio, with over 1,000 granted patents or applications extending to 2044, combined with proprietary manufacturing processes delivering off-the-shelf cellular medicines, positions it well to capitalise on this new technology.
Bottom Line?
Mesoblast’s CAR platform acquisition signals a strategic push to elevate MSC therapies’ precision and potency, but clinical validation and regulatory pathways remain key hurdles ahead.
Questions in the middle?
- How soon will Mesoblast initiate clinical trials incorporating the CAR-engineered MSCs?
- What regulatory challenges might arise with genetically engineered MSC therapies compared to existing products?
- Could the CAR platform enable Mesoblast to enter new autoimmune disease markets beyond current inflammatory targets?